Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
2.70% $0.616
America/New_York / 18 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 6.17 mill |
EPS: | -6.25 |
P/E: | -0.100 |
Earnings Date: | Apr 18, 2024 |
SharesOutstanding: | 10.01 mill |
Avg Daily Volume: | 1.736 mill |
RATING 2024-04-18 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.100 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -0.100 | industry: PE 18.71 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.504 - 0.676 ( +/- 14.58%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-11 | Ben-tzvi Avraham | Buy | 100 000 | Common Stock |
2024-04-11 | Natan David | Buy | 100 000 | Common Stock |
2024-04-11 | Mcmurdo Matthew Charles | Buy | 100 000 | Common Stock |
2024-04-11 | Lazar David E. | Buy | 100 000 | Common Stock |
2024-04-05 | Lazar David E. | Buy | 200 000 | Series E Convertible Preferred Stock |
INSIDER POWER |
---|
-75.94 |
Last 97 transactions |
Buy: 3 423 408 | Sell: 6 921 404 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.616 (2.70% ) |
Volume | 0.204 mill |
Avg. Vol. | 1.736 mill |
% of Avg. Vol | 11.77 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.